Acetamide, N-[2-[(5-chloro-2 methoxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]-inhibits pro-matrix metalloproteinase activation and can be used to prevent, treat or ameliorate MMP9 and/or MMP13-mediated syndromes.

MMP-9-IN-6 is an MMP-9 inhibitor with an IC50 value of 50 μM and good anti-ulcer efficacy.MMP-9-IN-6 has potential anti-tumor activity and can be used to study tissue remodeling, wound repair and atherosclerosis.

MMP-12 Inhibitor is a selective inhibitor of MMP-12 with IC50s of 2, 160, 320, and 22.3 nM for human, mouse, rat, and sheep MMP-12.

MMP-7-IN-3 is a potent, selective MMP-7 inhibitor that effectively suppresses the progression of kidney fibrosis in a mouse model with unilateral ureteral obstruction [1].

MMP-7-IN-2 acts as a selective and potent MMP7 inhibitor and can be used to study inflammatory responses and vascular-related diseases.

MMP-3 Inhibitor acetate is a cell-permeable and potent inhibitor of human MMP-3.

MMP-9-IN-8 (Compound 3), an MMP-9 inhibitor, exhibits inhibitory activities of 42.16% at 10 μM and 58.28% at 50 μM. Additionally, MMP-9-IN-8 demonstrates anti-cancer properties, inducing apoptosis in MCF-7 cells with an IC50 value of 23.42 μM [1].

BPHA (MMP-2/MMP-9 Inhibitor II) is a potent, selective and orally active inhibitor of MMP-2, MMP-9 and MMP-14 with IC50s of 12 nM, 16 nM and 17 nM, respectively.BPHA does not inhibit MMP-1, -3 and -7 (IC50s of 974, >1000 and 795 nM, respectively).BPHA has anti-angiogenic and BPHA has anti-angiogenic and anti-tumor activities.

DB04760 is a highly selective, non-zinc-chelating inhibitor of MMP-13 (IC50: 8 nM). DB04760 obviously decreases paclitaxel neurotoxicity and has anticancer activity.

MMP13-IN-2 is a highly potent, selective, and orally active inhibitor of MMP-13. It demonstrates exceptional potency against MMP-13, with an IC50 value of 0.036 nM, and exhibits selectivities greater than 1,500-fold over MMP-1, 3, 7, 8, 9, 14, and TACE. Moreover, MMP13-IN-2 possesses the capability to effectively inhibit collagen release from cartilage in vitro. Consequently, MMP13-IN-2 holds great potential for advancing research on collagenase-related diseases.

MMP13-IN-5 (compound 13m) is a potent, selective MMP-2/MMP-13 inhibitor with IC50 values of 3.6 μM for MMP-2 and 14.6 μM for MMP-13, implicated in the pathology of osteoarthritis (OA) [1].

MMP inhibitor I is a peptide inhibitor of matrix metalloproteinase-1 (MMP-1), MMP-2, and MMP-3 (IC50s = 1.3, 30, and 150 μM, respectively). It is selective for MMP-1, MMP-2, and MMP-3 over the proteases thermolysin, urease, trypsin, α-chymotrypsin, plasmin, and elastase at concentrations up to 4 mM.

MMP-1-IN-1 is a highly potent MMP-1 inhibitor with an IC 50 of 0.034 μM .

MMP-9-IN-5 is an MMP-9 inhibitor with an IC50 value of 4.49 nM and is able to form hydrogen bonds with MMP-9. MMP-9-IN-5 also inhibits AKT activity with an IC50 value of 1.34 nM. MMP-9-IN-5 exhibits cytotoxicity, induces apoptosis and can be used in cancer research.

MMP13-IN-3 is >1000 selective over other MMPs. MMP13-IN-3 is an effective, selective, and orally active MMP-13 inhibitor (IC50=1 nM) for the potential treatment of osteoarthritis.

MMP13-IN-4 (compound 13) is a potent, selective MMP-13 inhibitor with an IC50 of 14.6 μM, implicated in the pathology of osteoarthritis (OA) [1].

MMP-145 is used as a protease inhibitor.

Tubulin/MMP-IN-1, a potent inhibitor of both tubulin and MMP, holds promise for cancer research. It effectively suppresses tubulin polymerization, induces G2/M phase cell cycle arrest, and promotes reactive oxidative stress (ROS) generation in HepG2 cells, ultimately triggering apoptosis via the mitochondrial-dependent apoptotic pathway.

MMP-13 Substrate, a compound utilized in osteoarthritis (OA) research [1], functions as a substrate for MMP-13.

MMP-9/MMP-13 Inhibitor I is a dual inhibitor of MMP-9 and MMP-13 with IC50 of both 0.9 nM. MMP-9/MMP-13 Inhibitor I is over 20 times more selective for MMP-9/MMP-13 than other MMPs.

MMP-2/MMP-9-IN-1 is a potent, highly selective and orally bioavailable inhibitor of type IV collagenases (MMP-9 and MMP-2) with an IC50 of 0.24 and 0.3 1 μM for MMP-9 and MMP-2, respectively. activity, which can be used to study cancer.

MMP-8 Inhibitor I is a selective inhibitor of the neutrophil collagenase matrix metalloproteinase-8 (MMP-8) with an IC50 value of 4 nM.

Matrix metalloproteinase-3 (MMP-3), also known as stromelysin-1, is a critical enzyme involved in tissue remodeling and repair through its role in degrading extracellular matrix proteins, facilitating cell migration. This enzyme has been implicated in various physiological processes including vascular remodeling associated with aneurysm formation, wound healing, the progression of atherosclerosis, and tumor initiation. MMP-3 inhibitor VIII, a cell-permeable sulfonamide-based hydroxamic acid, effectively inhibits MMP-3 by binding to its active site (Ki = 23 nM), thus blocking its enzymatic activity. Additionally, this inhibitor has been demonstrated to suppress the activity of mouse macrophage metalloelastase MME/MMP-12, with an IC50 value of 13 nM, highlighting its potential utility in research on tissue remodeling and disease processes involving MMPs.

Tubulin/MMP-IN-2, a dual inhibitor of tubulin and matrix metalloproteinases (MMPs), effectively inhibits tubulin polymerization and induces cell apoptosis. It demonstrates inhibitory activities against MMP-2, MMP-3, and MMP-9, with IC50 values of 24.95 μM, 31.60 μM, and 22.37 μM, respectively. This compound is utilized in cancer research.

MMP-9-IN-4 is an inhibitor of MMP-9 and interacts with MMP-9 to form H-π with an IC50 value of 7.46 nM. MMP-9-IN-4 also inhibits AKT activity with an IC50 value of 8.82 nM. MMP-9-IN-4 induces apoptosis, shows cytotoxicity and can be used to study Cancer.

MMP-3 Inhibitor is a peptide matrix metalloproteinase-3 (MMP-3) inhibitor with a Ki value of 95 nM.MMP-3 inhibitor has anticancer and antitumor activity.

MMP-9-IN-3 is an MMP-9 inhibitor (IC50: 5.56 nM) that forms hydrogen bonds with MMP-9. MMP-9-IN-3 inhibits AKT activity (IC50: 2.11 nM). mmp-9-IN-3 is cytotoxic and induces apoptosis. mmp-9-IN-3 can be used to study cancer.

MMP2-IN-3 is a potent inhibitor of matrix metalloproteinases (MMP-2) (IC50: 31 μM). MMP2-IN-3 inhibits MMP-9 and MMP-8 with IC50s of 26.6 and 32 μM, respectively.

MMP2-IN-2 is a selective MMP-2 (matrix metalloproteinase) inhibitor with potential anticancer and antitumor activity, inhibits MMP-13, MMP-9, and MMP-8, and can be used in the study of cancer and immune disorders.

MMP-2/9-IN-1 (Compound 4a) is a potent dual inhibitor of MMP-2 (IC50: 56 nM) and MMP-9 (IC50: 38 nM). leading to DNA fragmentation.

MMP-9 inhibitor I is an inhibitor of matrix metalloproteinase-9 (MMP-9) that is selective over MMP-1 and MMP-13 (IC50s = 5, 1,050, and 113 nM, respectively). It also decreases the activity of TNF-α converting enzyme (TACE) in a dose-dependent manner (IC50 = 0.54 μM). MMP-9 inhibitor I decreases TNF-α secretion stimulated by LPS in BV-2 microglial cells when used at concentrations of 50 and 100 μM.

MMP-9-IN-1 is an inhibitor of specific matrix metalloproteinase-9 (MMP-9).

MMP2-IN-1 shows siganificant antiproliferative activity in certain cancer cells through arresting the cell cycle and inducing apoptosis. MMP2-IN-1 is a moderate potenet inhibitor of MMP2 (IC 50 = 6.8 μM)[1].

MMPP is a novel VEGFR2 inhibitor with anti-inflammatory and potential anticancer activity, inhibits STAT3, inhibits angiogenesis via VEGFR2/AKT/ERK/NF-kappaB pathway, and can be used to alleviate myocardial injury.

ARP-100 (MMP-2 Inhibitor III) is a potent and selective matrix metalloproteinase MMP-2 inhibitor (IC50=12 nM). ARP-100 interacts with the S1' pocket of MMP-2 and exhibits anti-invasive properties in an in vitro invasion Matrigel model. ARP-100 has low inhibitory activity against MMP-1 (>50 μM), MMP-3 (4.5 μM), MMP-7 (>50 μM) and MMP-9 (0.2 μM)[1][2].

Doxycycline (Doxiciclina) belongs to the tetracycline class of antibiotics and is a broad-spectrum metalloproteinase (MMP) inhibitor with oral activity. Doxycycline has antibacterial activity and antitumor activity.

Polygalacic acid (Virgaureagenin G)(PA) significantly improves cholinergic system reactivity, as indicated by decreased acetylcholinesterase (AChE) activity, increases choline acetyltransferase (ChAT) activity, and elevates levels of acetylcholine (ACh) in the hippocampus and frontal cortex, PA also significantly ameliorates neuroinflammation and oxidative stress in mice; suggest that PA might exert a significant neuroprotective effect on cognitive impairment, driven in part by the modulation of cholinergic activity and neuroinflammation. Polygalacic acid shows significant postingestive effects on Spodoptera littoralis larvae.

(-)-Epigallocatechin, the predominant flavonoid in green tea, possesses the unique ability to attach to unfolded native polypeptides, thereby inhibiting their transformation into amyloid fibrils.

3-Aminopropionitrile fumarate (2:1) (β-Aminopropionitrile fumarate) is an organic compound and antirheumatic agent used in veterinary medicine.

Stigmasterol (Stigmasterin) is found in the fats and oils of soybean, calabar bean and rape seed, as well as several other vegetables, legumes, nuts, seeds, and unpasteurized milk. Stigmasterol has been focused on the cholesterol-lowering activity and is valued as an anti-stiffness factor in the therapy of rheumatic diseases.

Astragaloside IV (AS-IV), an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells. Astragaloside IV is a bioactive saponin first isolated from the dried plant roots of the genus Astragalus, which is used in traditional Chinese medicine.1 It dose-dependently inhibits human adenovirus type 3 (HAdV-3) in A549 cells (IC50 = 23 μM; LC50 = 865 μM).It inhibits replication of HAdV-3 and decreases HAdV-3-induced apoptosis. It has diverse protective effects for the cardiovascular, immune, digestive, and nervous systems. In particular, it reduces myocardial infarct size in dogs when administered prior to coronary ligation and reduces reperfusion arrhythmias in isolated rat hearts.

1. ISOGINKGETIN (4',4'''-Dimethylamentoflavone), a compound derived from the leaves of Ginkgo biloba, to up-regulate adiponectin secretion with potency comparable to that of rosiglitazone, a known modulator of adiponectin production. 2. Isoginkgetin has anti-tumor activity, the mechanistic basis is splicing inhibition , thus, pre-mRNA splicing inhibitors may represent a novel avenue for development of new anti-cancer agents.3. Isoginkgetin can inhibit tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression. 4. Isoginkgetin (0.3mg/kg ip for 3d) can reduce the level of O2·- in plasma and erythroeyte and sometimes increase the activity of SOD in anoxic rats, the action being stronger than aspirin.

(-)-Arctigenin ((-)-Arctigenin) is found in burdock. (-)-Arctigenin is isolated from Cnicus benedictus, Forsythia viridissima, Arctium lappa, Ipomoea cairica and others (CCD). Arctigenin is a lignan found in certain plants of the Asteraceae, including the Greater burdock (Arctium lappa) and Saussurea heteromalla. It has shown antiviral and anticancer effects. It is the aglycone of arctiin.

PG-116800 (PG-530742) is a matrix metalloproteinase (MMP) inhibitor. PG-116800 can be used in studies about the treatment of osteoarthritis.

Histatin 5 acetate inhibits the activity of the host matrix metalloproteinases MMP-2 and MMP-9 with IC50s of 0.57 and 0.25 μM, respectively.

Hydrangenol is a natural product and can be isolated from Hydrangea serrata leaves. Hydrangenol is an antiphotoaging compound with oral activity. Hydrangenol can reduce MMP and inflammatory cytokine expression and increase moisturizing factors and antioxidant genes level, result in preventing wrinkle formation.

CTTHWGFTLC, CYCLIC acetate is an inhibitor for matrix metalloproteinases (MMP)-2 and MMP-9. It is also called type IV collagenase or gelatinase. Gelatinases are potential targets of therapeutic intervention in cancer, and inhibitors of these enzymes can prevent tumor progression.

PF 00356231 is a selectivity inhibitor MMP-12 and can be used in studies about the treatment of emphysema and chronic obstructive pulmonary disease (COPD).

ND-322 HCl (ND 322 Hydrochloride) is a selective inhibitor of MT1-MMP and MMP2 and reduces in vitro melanoma cell growth, migration and invasion.

JG26 is a potent inhibitor of ADAM17, which can inhibit ADAM8, ADAM17, ADAM10 and MMP-12, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM, respectively, and can be used to study the immune system of the body.